drugset / Trial / NCT07623200
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.
Timeline
- Start
- 2026-07-31
- Primary completion
- 2029-06-15
- Completion
- 2030-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANA | Unknown | — | — |
| Subject | INCA033989 | Unknown | — | Intravenous |
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | — | — |
| Subject | Ropeginterferon alfa-2b | Protein / enzyme biologic | — | — |